The Xiapex will no longer be available over-atlantic from january 2020!

The news fell like a cleaver, Xiapex, a spectacular injectable treatment for Dupuytren's disease, saw its marketing suddenly stop.

The biopharmaceutical company Sobi (Swedish Orphan Biovitrum), specialized in rare diseases, and distributor of Xiapex in the EU, the other countries of Europe and the Middle East has just announced the total cessation of its marketing with effect on 03/01/2020.

Indeed, the cooperation agreement which binds them to the American company that produces Xiapex has just ended (12/31/2019), not for safety or efficiency reasons but only for commercial reasons.

Xiapex has had its marketing authorization withdrawn in Belgium, which means for patients who have benefited from it since 2012, the disappearance of this therapeutic alternative.

Other solutions of course exist for the treatment of Dupuytren's disease. Dr D’Agostino is at your disposal to detail them.